Additionally, when almonertinib is combined with other drugs that are substrates for CYP3A4, P-gp or BCRP in NSCLC patients, special attention to DDIs attributed to this inhibitory effect is essential. The gene discussed is CYP3A4; the disease is non-small cell lung carcinoma.